Xenon Pharmaceuticals Inc (XENE NASDAQ) stock market data APIs
$33.0452
-0.55(-1.7%)
as of July 10, 2025
Try our APIs with
free plan!
Xenon Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Prev. Close
33.0452
Open
32.4927
High
33.2462
Low
32.1143
52 wk Range
26.74-46
Market Cap
2 508 M
Shares Outstanding
76 734 K
Revenue
7 500 K
EPS
-0.83
Beta
1.097
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Xenon Pharmaceuticals Inc data using free add-ons & libraries
Get Xenon Pharmaceuticals Inc Fundamental Data
Xenon Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 7 500 K
- EBITDA: -290 361 984
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-04
- EPS/Forecast: -0.8972
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Xenon Pharmaceuticals Inc News
New
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. RBC Capital maintained its Outperform rating on Xenon Pharmaceuticals ...
H.C. Wainwright reaffirms Buy rating on Xenon Pharmaceuticals stock at $53
Investing.com - H.C. Wainwright has reiterated its Buy rating and $53.00 price target on Xenon Pharmaceuticals (NASDAQ:XENE), highlighting the company’s leadership in ion channel drug development ...
Xenon Pharmaceuticals added to Russell 3000 and 2000 indexes
VANCOUVER/BOSTON - Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a biopharmaceutical company with a market capitalization of $2.47 billion, has been added to the Russell 3000 and Russell 2000 Indexes as p...
Xenon joins Russell 3000 and Russell 2000 indexes
* Xenon Pharmaceuticals (NASDAQ:XENE [https://seekingalpha.com/symbol/XENE]) on Friday said the company has been added to the broad-market Russell 3000 and small-cap Russell 2000 Indexes as part of ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
